Cell Biotech Co

Cell Biotech Co Days Payable Outstanding

The Days Payable Outstanding (DPO) of Cell Biotech Co (049960.KQ) as of Nov 17, 2026 is 11.54. In the previous year, Days Payable Outstanding (DPO) was 17.92 — a change of -35.63% (lower).

Days Payable Outstanding

11.54

YoY

-35.63%

Last updated:

Days Payable Outstanding (DPO) of Cell Biotech Co is 2025 11.54 . Days Payable Outstanding (DPO) of Cell Biotech Co was 2024 17.92 . It decreases by -35.63% lower compared to the previous year.

The Cell Biotech Co Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2018
29.35 KRW
Jan 1, 2019
34.27 KRW
Jan 1, 2020
29.84 KRW
Jan 1, 2021
39.94 KRW
Jan 1, 2022
39.75 KRW
Jan 1, 2023
14.25 KRW
Jan 1, 2024
17.92 KRW
Jan 1, 2025
11.54 KRW
The Cell Biotech Co Days Payable Outstanding history
YEARDays Payable OutstandingYoY
11.54-35.63%
17.92+25.77%
14.25-64.15%
39.75-0.47%
39.94+33.84%
29.84-12.92%
34.27+16.75%
29.35+0.79%
29.12-7.35%
31.44-7.15%
33.86+3.01%
32.87—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Biotech Co Stock analysis

What does Cell Biotech Co do? Cell Biotech Co., Ltd. generates revenue through the production and sale of probiotic lactobacillus products. The company manufactures lactic acid bacteria (LAB) powders, which serve as raw materials for foods and medicines targeting immunization enhancement and digestion improvement. Finished products containing LABs are sold for intestinal health improvement, carcinogen inhibition, and calcium supplementation, distributed domestically and internationally. The firm focuses on functional health applications within the probiotics market. The company's primary customers are domestic and international food and pharmaceutical manufacturers seeking functional ingredients, as well as end consumers purchasing finished probiotic products. LAB powders are supplied to food and medicine producers, while finished products reach consumers directly for health benefits. Distribution channels include both local and global markets, emphasizing the functional health segments of the industry. Cell Biotech's product portfolio centers on LAB-based solutions for health enhancement, with no additional brands or external partnerships mentioned in the business description. The company operates solely within the probiotics sector, leveraging its research and development capabilities to create products aligned with digestive and immune health needs. Cell Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Biotech Co stock

Days Payable Outstanding (DPO) of Cell Biotech Co is 11.54 in 2025.

Days Payable Outstanding (DPO) of Cell Biotech Co changed from 17.92 to 11.54, representing a -35.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Cell Biotech Co since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Cell Biotech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Cell Biotech Co

All Key Metrics — Cell Biotech Co